Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled Phase 3 trial of IPP-201101 in systemic lupus erythematosus
2015-003341-25Phase 3Completed
- Sponsor
- ImmuPharma
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing IPP-201101 200 mcg + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary SRI response at week 52. Started Mar 2016; status: completed.
02
Drugs
forigerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2015-003341-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003341-25.